psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling | |
Ding, Jin[1]; Wen, Wen[1]; Xiang, Daimin[1]; Yin, Peipei[1,2]; Liu, Yanfang[3]; Liu, Chang[2]; He, Guoping[1]; Cheng, Zhuo[1]; Yin, Jianpeng[5]; Sheng, Chunquan[4] | |
2015 | |
卷号 | 6期号:13页码:11627 |
URL标识 | 查看原文 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/4347732 |
专题 | 暨南大学 |
作者单位 | 1.[1]Second Mil Med Univ, Int Cooperat Lab Signal Transduct, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China 2.[2]Shanghai Inst Pharmaceut Ind, Dept Pharmacol, Shanghai, Peoples R China 3.[3]Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci Analyt Chem, Dalian, Peoples R China 4.[4]Second Mil Med Univ, Coll Pharm, Shanghai, Peoples R China 5.[5]Natl Ctr Drug Screen, Shanghai, Peoples R China 6.[6]Jinan Univ, Coll Pharm, Guangzhou, Guangdong, Peoples R China 7.[7]Natl Ctr Liver Canc, Shanghai, Peoples R China |
推荐引用方式 GB/T 7714 | Ding, Jin[1],Wen, Wen[1],Xiang, Daimin[1],et al. psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling[J],2015,6(13):11627. |
APA | Ding, Jin[1].,Wen, Wen[1].,Xiang, Daimin[1].,Yin, Peipei[1,2].,Liu, Yanfang[3].,...&Wang, Hongyang[1,7].(2015).psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.,6(13),11627. |
MLA | Ding, Jin[1],et al."psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling".6.13(2015):11627. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论